Lydfilen for denne episode er muligvis beskadiget
How to fix it?
OM DENNE EPISODE
Listen to Tina Wang, Statistician, and Dr. Paul Schuette, Deputy Division Director, in the Office of Biostatistics Division of Analytics and Informatics within FDA’s Center for Drug Evaluation and Research discuss FDA’s experiences with a centralized statistical monitoring tool.
Engelsk
USA
SØG BLANDT TIDLIGERE EPISODER
Søg efter gamle afsnit af FDA CDER Small Business and Industry Assistance (SBIA) Chronicles.
ANDRE EPISODE I DENNE PODCAST
The CDER NextGen Portal (or the “Portal” for short) has made it easier than ever for regulated industry to communicate with the FDA.
The FDA Compounding Incidents Program: Adverse Events Associated with Compounded Drugs from Outsourcing Facilities
Continuous manufacturing (CM) technology has the potential to improve product quality and reliability, lower manufacturing costs, reduce waste, decrease inventory, and increase manufacturing flexibility and agility in response to product demand.
FDA Regulation and Quality Considerations for Cannabis and Cannabis-Derived Compounds
The Role of Pharmacodynamic Biomarkers in Biosimilar Drug Development
Ansvarsfraskrivelse: Podcasten og kunstværket, der er indlejret på denne side, er fra U.S. Food and Drug Administration, Center for Drug Evaluation and Research, som tilhører dens ejer og ikke er tilknyttet eller godkendt af Listen Notes, Inc.
REDIG
Tak fordi du hjælper med at holde podcast-databasen opdateret.
